Harnessing impaired energy metabolism in cancer cell: Small molecule- mediated ways to regulate tumorigenesis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 272-279

  Shroff, Govardhan K ^a   Kuna, Ramyasri ^a   Dirsipam, Kethora ^a   Yalagala, Ravishekar ^a   Mitra, Prasenjit ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

Aerobic glycolysis; Akt; Glutaminolysis; Hexokinase II; mTOR; Myc; Warburg effect

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; AMINO ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HEXOKINASE 2; LIPID; NUCLEIC ACID; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG;

AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; CANCER CELL; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; ENERGY METABOLISM; FATTY ACID SYNTHESIS; GLYCOLYSIS; HUMAN; METASTASIS; MICROENVIRONMENT; NONHUMAN; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 79954560436     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152011795347531     Document Type: Review

References (65)

1. Seyfried, T.N.; Shelton, L.M. Cancer as a metabolic disease. Nutr. Metab. (Lond.), 2010, 7:7. doi:10.1186/1743-7075-7-7. http://www.nutritionandmetabolism.com/content/7/1/7.
2. Warburg, O. On the origin of cancer cells. Science, 1956, 123(3191), 309-14.
3. Warburg, O.; Posener, K.; Negelein, E. Ueber den Stoffwechsel der Tumoren. Biochem. Z., 1924, 152, 319-44.
4. Ciampi, R.; Vivaldi, A.; Romei, C.; Del Guerra, A.; Salvadori, P.; Cosci, B.; Pinchera, A.;Elisei, R. Expression analysis of facilitative glucose transporter(GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol. Cell. Endocrinol., 2008, 291(1-2), 57-62.
5. Wincewicz, A.; Baltaziak, M.; Kanczuga-Koda, L.; Sulkowska, U.; Sulkowski S. GLUT-1 and Bcl-xl in relation to erythropoietin in human colorectal adenocarcinoma. Hepatogastroenterology, 2010, 57(101), 741-45.
6. Deron, P.; Vangestel, C.; Goethals. I.; De Potter, A.; Peeters, M.; Vermeersch, H.; Van de Wiele, C. FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis. Nuklearmedizin, 2010, 50(1), 15-21.
7. Singer, K.; Kastenberger, M.; Gottfried, E.; Hammerschmied, C.G.; Büttner, M.; Aigner, M.; Seliger, B.; Walter, B.; Schlösser, H.; Hartmann, A.; Andreesen, R.; Mackensen, A.; Kreutz, M. Warburg phenotype in renal cell carcinoma: High expression of glucosetransporter 1 (GLUT-1) correlates with low CD8 (+) T-cell infiltration in the tumor. Int. J. Cancer. [Online early access] DOI: 10.1002/ijc.25543.Published Online: July 6 2010. http://onlinelibrary.wiley.com (accessed Dec 19, 2010).
8. Wood, T.E.; Dalili, S.; Simpson, C.D.; Hurren, R.; Mao, X.; Saiz, F.S.; Gronda, M.; Eberhard, Y.; Minden, M.D.; Bilan, P.J.; Klip, A.; Batey, R.A.; Schimmer, A.D. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol. Cancer Ther., 2008, 7(11), 3546-3555.
9. Ishikawa, N.; Oguri, T.; Isobe, T.; Fujitaka, K.; Kohno, N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn. J. Cancer Res., 2001, 92(8), 874-879.
10. Wilson, J.E. Isozymes for mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol., 2003, 206, 2049-2057.
11. Mathupala, S.P.; Ko Y.H.; Pedersen, P.L. Hexokinase-2 bound to mitochondria: Cancer's stygian link to the pivotal target for effective therapy. Semin. Cancer. Biol., 2009, 19(1), 17-24.
12. Ko, Y.H.; Pedersen, P.L.; Geschwind, J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer lett., 2001, 173(1), 83-91.
13. Cao, X.; Bloomston, M.; Zhang, T.; Frankel, W.L.; Jia, G.; Wang, B.; Hall, N.C.; Koch, R.M.; Cheng, H.; Knopp, M.V. Synergistic anti pancreatic tumor effect by simultaneously targeting hypoxic tumor cells with HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res., 2008, 14(6), 1831-1839.
14. Park, H.S.; Chung, J.W.; Jae, H.J.; Kim, Y.I.; Sonk, R.; Lee, M.J. FDG-PET for evaluating the antitumor effect intra-arterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. Korean J. Radiol., 2007, 8(3), 216-24.
15. Dombrauckas, J.D.; Santasiero, B.D.; Mesecar, A.D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry, 2005, 44(21), 9417-9429.
16. Boxer, M.B.; Jiang, J.K.; Vande Heiden, M. G.; Shen, M.; Skoumbourdis, A.P.; Southall, N.; Veith, H.; Leister, W.; Austin, C.P.; Park, H.W.; Inglese, J.; Cantley, L. C.; Auld, D.S.; & Thomas, C.J. Evaluation of substituted N, N'-di aryl sulphonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem., 2010, 53(3), 1048-55.
17. Papandreou, I.; Goliasova, T.; Denko, N.C. Anticancer drug that target metabolism: Is dichloroacetate the new paradigm? Int. J. Cancer., 2011, 128, 1001-8.
18. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K; Porter, C. J.; Andrade, M.A.; Thebaud, B.; Michelakis, E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11(1), 37-51.
19. Michelakis, E.D.; Sutendra, G.; Dromparis, P.; Webster, L.; Haromy, A.; Niven, E.; Maguire, C.; Gammer, T. L.; Mackey, J.R.; Fulton, D.; Abdulkarim, B.; McMurtry, M. S.; Petruk, K. C. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med., 2010, 2(31), 31ra34.
20. Kroemer, G.; Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13(6), 472-82.
21. Mueller-Klieser, W. Metabolic micromilieu in tumours. Nuklearmedizin, 2010, 49(Suppl1):S16-S20.
22. Fischer, K.; Hoffmann, P.; Voelkl, S.; Meidenbauer, N.; Ammer J.; Edinger, M.; Gottfried, E.; Schwarz, S.; Rothe, G.; Hoves, S.; Renner, K.; Timischl, B.; Mackensen, A.; Kunz-Schughart, L.; Andreesen, R.; Krause, S. W.; Kreutz, M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 2007, 109(9), 3812-3819.
23. Feron, O. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol., 2009, 92(3), 329-333.
24. Sonveaux, P.; Végran, F.; Schroeder, T; Wergin, M. C; Verrax, J; Rabbani, Z. N; De Saedeleer, C. J; Kennedy, K. M; Diepart, C; Jordan, B.F.; Kelley, M. J; Gallez, B; Wahl, M.L.; Feron, O.; Dewhirst, M.W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008, 118(12), 3930-3942.
25. Vaupel P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 2007, 26(2), 225-39.
26. Fang, J.; Quinonees, Q.J.; Holman, T.L.; Morowitz, M.J.; Wang, Q.; Zhao, H.; Sivo, F.; Maris, J.M.; Wahl, M.L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol., 2006, 70(6), 2108-15.
27. Froberg, M.K.; Gerhart, D.Z.; Enerson, B.E.; Manivel, C.; Guzman-Paz M.; Seacotte, N.; Drewes, L.R. Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport., 2001, 12(4), 761-65.
28. Pinheiro, C.; Longatto-Filho, A.; Scapulatempo, C.; Ferreira, L.; Martins, S.; Pellerin, L.; Rodrigues, M.; Alves, V. A.; Schmitt, F.; Baltazar, F. Increased expression of monocarboxylate transporters 1,2 and 4 in colorectal carcinoma. Virchows. Arch., 2008, 452(2), 139-146.
29. Swinnen, J.V.; Brusselmans, K.; Verhoeven, G. Increased Lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Nutr. Metab. Care, 2006, 9(4), 358-365.
30. Medes, G.; Thomas, A.; Weinhouse, S. Metabolism of neoplastic tissue IV: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res., 1953, 13(1), 27-29.
31. Ookhtens, M.; Kannan, R.; Lyon, I.; Baker N. Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol., 1984, 247(1Pt 2), R146-R153.
32. Sabine J.R.; Abraham, S.; Chaikoff, I.L. Control of lipid metabolism in hepatomas: insensitivity of rate of fatty acid and cholesterol synthesis by mouse hepatoma BW7756 to fasting and to feedback control. Cancer Res., 1967, 27(4), 793-799.
33. Baggeto, L.G. Deviant energetic metabolism of glycolytic cancer cells. Biochimie., 1992, 74(11), 959-974.
34. Crabtree, H.G. Observations on the carbohydrate metabolism of tumors. Biochem. J., 1929, 23(3), 536-545.
35. Wellen, K.E.; Hatzivassiliou, G.; Sachdeva, U.M.; Bui, T.V.; Cross, J.R.; Thompson, C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science, 2009, 324(5930), 1076-1080.
36. Bauer, D.E.; Hatzivassiliou, G.; Zhao, F.; Andreadis, C.; Thompson, C.B. ATP-citrate lyase is an important component of cell growth and transformation. Oncogene, 2005, 24(41), 6314-6322.
37. Hatzivassiliou, G.; Zhao, F.; Bauer, D. E.; Andreadis, C.; Shaw, A.N.; Dhanak, D.; Hingorani, S.; Tuveson, D.A.; Thompson, C.B. ATP-citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8(4), 311-321.
38. Migita, T.; Narita, T.; Nomura, K.; Miyagi, E.; Inazuka, F.; Matsuura, M.; Ushijimam, M.; Mashima, T.; Seimiya, H.; Satoh, Y.; Okumura, S.; Nakagawa, K.; Ishikawa, Y. ATP-citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res., 2008, 68(20), 8547-54.
39. Eliasz, S.; Liang, S.; Chen, Y.; DeMarco, M.A.; Machek, O.; Skuch, AS.; Miele, L.; Boccheta, M. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-IR pathway. Oncogene, 2010, 29(17), 2488-2498
40. Feron, O. Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol., 2009, 92(3), 329-333.
41. Vander Heiden, M.G.; Cantley, L.C.; Thomson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 2009, 324(5930), 1029-1033.
42. Young, C. D.; Nolte, E. C.; Lewis, A.; Serkova, N.J.; Anderson, S.M. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res., 2008, 10(4), R70.
43. Shackelford, D.B.; Shaw, R.J. The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat. Rev. Cancer, 2009, 9(8), 563-575.
44. Garcia-Echeverria, C. Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg. Med. Chem. Lett., 2010, 20(15), 4308-4312.
45. O'Reilly, K.E.; Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hoffmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508.
46. Shor, B.; Gibbons J.J.; Abraham, R.T.; Yu, K. Targeting mTOR globally in cancer thinking beyond rapamycin. Cell cycle, 2009, 8(23), 3831-3837.
47. Apsel, B.; Blair, J.A.; Gonzalez, B.; Nazif, T.M.; Feldman, M.E.; Aizenstein, B.; Hoffman, R.; Williams, R.L.; Shokat, K.M.; Knight, Z.A. Targeted poly pharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol., 2008, 4(11), 691-699.
48. Sparks, C.A.; Guertin, D.A. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene, 2010, 29(26), 3733-3744.
49. Nardella, C.; Carracedo, A.; Alimonti, A.; Hobbs, R.M.; Closshesy J.G.; Chen Z. Differential requirement of mTOR in post mitotic tissues and tumorigenesis. Sci. Signal, 2009, 2(55), ra2.
50. Balgi, A.D.; Fonseca, B.D.; Donohue, E.; Tsang, T.C.; Lajoie, P.; Proud, C.G.; Nabi, I.R.; Roberge, M. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS. One, 2009, 4(9), e7124.
51. Kourelis, T.V.; Seigel, R.D. Metformin and cancer: new applications for an old drug. Med. Oncol.[Online early access]. DOI:10. 1007/s12032-011-9846-7. Published Online: Feb 8, 2010. http://www.springerlink.com/content/v174h0x552641167, (accessed Feb 27, 2011).
52. Memmot, R.M.; Mercado, J.R.; Maier, C.R.; Kawabata, S.; Fox, S.D.; Dennis, P.A. Cancer Prev. Res(Phila).,2010, 3(9), 1066-1076.
53. Buzzai, M.; Jones, R.G.; Amaravadi, R.K.; Lum, J.J.; DeBerardinis, R.J.; Zhao, F.; Viollet, B.; Thompson, C.B. Systematic treatment with the antidiabetic drug Metformin selectively impairs p53-deficient tumor cell growth. Cancer Res., 2007, 67(14), 6745-6752.
54. Liu, B.; Fan, Z.; Edgerton, S.M.; Deng, X.S.; Alimova, I.N.; Lind, S.E.; Thor, A.D. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle, 2009, 8(13), 2031-2040
55. Dann, S.G.; Thomas, G. The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett., 2006, 580(12), 2821-2829.
56. Hara, K.; Yonezawa, K.; Weng, Q.P.; Kozlowski, M. T.; Belham, C.; Avruch, J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4EBP1 through a common effector mechanism. J. Biol. Chem., 1998, 273(23), 14484-14494.
57. Krause, U.; Bertrand, L.; Maisin, L.; Rosa, M.; Hue, L. Signaling pathways and combinatory effects of insulin and amino acids in isolated rat hepatocytes. Eur. J. Biochem., 2002, 269(15), 3742-3750.
58. DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirements for proteins and nucleotide synthesis. Proc. Natl. acad. Sci., 2007, 104(49), 19345-19350.
59. Wise, D.R.; Thompson, C. B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci., 2010, 35(8), 427-433.
60. Yuneva, M.; Zamboni, N.; Oefner, P.; Sachidanandam, R.; Lazebnik, Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol., 2007, 178(1), 93-105.
61. Esslinger, C. S.; Cybulski, K. A.; Rhoderick, J. F. N gamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorganic. Med. Chem., 2005, 13(4), 1111-1118.
62. Moreadith, R.W.; Lehninger, A.L. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mito chondrial NAD(P)+-dependent malic enzyme. J. Biol. Chem., 1984, 259(10), 6215-6221.
63. Grewer, C.; Grabsch, E. New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak. J. Physiol., 2004, 557(Pt 3), 747-759.
64. Pearce, N.J.; Yates, J. W.; Berkhout, T.A.; Jackson, B.; Tew, D.; Boyd, H.; Camilleri, P.; Sweeney, P.; Gribble, A.D.; Shaw, A.; Groot, P.H. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem. J., 1998, 334(Pt1).
65. Tennant, D.A.; Durán, R.V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer, 2010, 10(4) 267-277.